Georgia is currently home to 1996 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Home OCT Fluid Visualization Agreement Study
NCT04907409
Recruiting
This is a single arm study of home monitoring with the NVHO for 5 weeks with office visits at enrollment, Week 1 and Week 5 (Exit Visit) and, when applicable, Interim Visit(s) triggered by ongoing review by the Reading Center. The study will enroll subjects diagnosed with NV-AMD in at least one eye with attention to the proportion of eyes with IRF and/or SRF. The enrolled eligible subjects will be instructed to self-image the study eye(s) once daily for 5 weeks using a NVHO device at home with s... Read More
Gender:
All
Ages:
55 years and above
Trial Updated:
03/08/2022
Locations: Georgia Retina, Marietta, Georgia
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
Prospective Global Registry for the Study of Chronic Total Occlusion Intervention
NCT02061436
Recruiting
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is increasingly being performed in patients with advanced coronary artery disease, but there is limited information on the techniques utilized and the procedural outcomes. The goal of this multicenter, investigator initiated registry is to collect information on treatment strategies and outcomes of consecutive patients undergoing CTO PCI among various participating centers. The information collected will be used to deter... Read More
Gender:
All
Ages:
All
Trial Updated:
03/08/2022
Locations: Piedmont Heart Institute, Atlanta, Georgia
Conditions: Coronary Artery Disease
Register for Updates
KRT-232 and TKI Study in Chronic Myeloid Leukemia
NCT04835584
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/04/2022
Locations: Georgia Cancer Center at Augusta University, Augusta, Georgia
Conditions: Chronic Myeloid Leukemia
Register for Updates
NOVOCART®3D for Treatment of Articular Cartilage of the Knee
NCT01957722
Recruiting
This study is to compare NOVOCART 3D relative to Microfracture for the treatment of knee cartilage defects. Efficacy will be evaluated by both pain and function. Safety will also be evaluated.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/01/2022
Locations: Glynn Brunswick Memorial Authority, Brunswick, Georgia
Conditions: Articular Cartilage of the Femoral Condyle Between 2-6cm2
Register for Updates
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
NCT03257033
Recruiting
The study is a multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2022
Locations: Piedmont-Columbus Regional - John B. Amos Cancer Center, Columbus, Georgia
Conditions: Locally Advanced Pancreatic Cancer
Register for Updates
Health and Resilience Projects: Foundations
NCT05253235
Recruiting
The Health and Resilience Project (HARP): Foundations is investigating the efficacy of the Strong African American Families (SAAF) intervention in promoting the health and well being of African American adolescents. Youth age 10-13 and their primary caregivers are randomly assigned to receive SAAF or to a control group. Participants complete baseline and follow-up measures regarding vulnerability to substance use based on a neuroimmune model of stress coping.
Gender:
All
Ages:
Between 10 years and 13 years
Trial Updated:
02/14/2022
Locations: Center for Family Research, Athens, Georgia
Conditions: Substance Use
Register for Updates
Compliance With Enhanced Recovery After Surgery Protocol (ERAS) in Surgical Patients
NCT03968666
Recruiting
The concept of "enhanced recovery" was introduced by European anesthesiologists and surgeons who challenged traditional clinical practices involved in peri-operative care in 1990s. The goal of enhanced recovery programs (ERP) is to maintain normal physiology thereby decreasing complications. It focuses on peri-operative optimization of patient care. It was originally created for open colorectal surgeries but now has shown benefit in various surgical specialities including thoracic surgery, vascu... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/14/2022
Locations: Augusta University, Augusta, Georgia
Conditions: Surgery, Anesthesia
Register for Updates
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study
NCT03545607
Recruiting
A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2022
Locations: Athersys Investigational Site 103, Augusta, Georgia
Conditions: Ischemic Stroke
Register for Updates
Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients
NCT05238220
Recruiting
The purpose of this study is to evaluate whether the use of the Viracor® CMV immunity assay at 6 months post-transplant in CMV high risk kidney transplant recipients would help identify those patients at higher risk of post-prophylaxis CMV viremia or disease and thereby select those patients in which a longer duration of valganciclovir prophylaxis would be beneficial.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/03/2022
Locations: Piedmont Atlanta Hospital, Atlanta, Georgia
Conditions: Kidney Transplant; Complications
Register for Updates
The EMPOWER Study: Endometriosis Diagnosis Using microRNA
NCT04598698
Recruiting
Endometriosis is a complex, heterogeneous disease that may present inconsistently across women. Using disease-specific biomarkers and advanced biostatistics, DotLab is developing a biomarker test to confirm the presence of endometriosis.This is a multi-center, prospective, observational, minimal risk study in women undergoing laparoscopy, laparotomy or other pelvic surgical procedure for endometriosis, infertility or another benign gynecological indication. Participants will undergo 2 study visi... Read More
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
01/11/2022
Locations: Academia of Women's Health and Endoscopic Surgery, Atlanta, Georgia
Conditions: Endometriosis
Register for Updates
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
NCT02675946
Recruiting
This is a multicenter, open-label study conducted in two phases: Phase 1 consisting of a CGX1321 Single Agent Dose Escalation Phase in solid tumors, CGX1321 Single Agent Dose Expansion Phase in GI tumors and Roll-over Cohort of CGX1321 and pembrolizumab in subjects who have progressed on single agent CGX1321 and Phase 1b consisting of CGX1321 in combination with pembrolizumab in colorectal tumors and CGX1321 in combination with encorafenib + cetuximab in BRAFV600E mutated colorectal tumors. Both... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: University Cancer & Blood Center (QCCA), Athens, Georgia
Conditions: Solid Tumors, GI Cancer
Register for Updates
Safety and Durability of Sirolimus for Treatment of LAM
NCT02432560
Recruiting
The MIDAS study aims to follow LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/11/2022
Locations: Emory University School of Medicine, Atlanta, Georgia
Conditions: Lymphangioleiomyomatosis
Register for Updates